Lotus to Commercialise Intas’s Prolia® (denosumab) Biosimilar in South Korea, Taiwan and South East Asia

Lotus Pharmaceutical announced that it has entered into a partnership with Intas Pharmaceuticals for the commercialisation of Intas’s Prolia® (denosumab) biosimilar in South Korea, Taiwan and certain markets in South East Asia.  According to the announcement, Intas will be responsible for development, manufacture and supply of the biosimilar, and Lotus will be responsible for the regulatory process and obtain commercialisation rights in those territories.